- Home
- MIST vs ELDN Comparison
MIST vs ELDN Comparison
Compare MIST & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | ELDN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 208.6M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIST | ELDN |
|---|---|---|
| Price | $1.59 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | ★ 1.3M | 705.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.80 | ★ 54.27 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $1.35 |
| 52 Week High | $3.06 | $4.60 |
Technical Indicators
Market Signals| Indicator | MIST | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 69.96 |
| Support Level | $1.38 | $2.48 |
| Resistance Level | $1.79 | $2.77 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 10.55 | 92.31 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.